Shares of Voyager Therapeutics Inc.
VYGR,
rallied 35% in premarket trading on Monday after the company announced a deal with Neurocrine Biosciences Inc.
NBIX,
to develop and commercialize gene therapies, including one that is being tested as a treatment for Parkinson’s disease. Neurocrine will make a $175 million upfront payment, including a $39 million equity investment, with up to $1.5 billion in potential milestones. Voyager’s stock has soared 148.7% over the past year, while the S&P 500
SPX,
is down 17.0%.
Business
Voyager, Neurocrine ink gene-therapy deal
[ad_1]
[ad_2]
